CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
rimonabant +1 moredrug
Likely dose
rimonabant 90 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00656487
NCT00656487Phase 2Completed
CompareCT.gov

Translational Center on the Clinical Neurobiology of Cannabis Addiction

The Scripps Research Institute·interventional·Posted Apr 11, 2008·Updated Jun 19, 2017

In Brief

A Phase 2 clinical trial evaluating rimonabant and placebo for Cannabis Dependence and Cannabis Withdrawal. Completed, enrolled 66 participants across 1 site.

Detailed Summary

The purpose of this study is to find out more about cognitive functioning in people who are cannabis dependent, relative to people who do not use cannabis, and how their brains process information after one month of not using cannabis. An additional goal is to characterize the severity of cannabis dependence using precipitated and naturalistic withdrawal with a double blind, placebo controlled, single administration of rimonabant. Research assessments occur bi-weekly throughout this 28 day study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCannabis Dependence, Cannabis Withdrawal
CountriesUnited States
CollaboratorsNational Institute on Drug Abuse (NIDA)

Timeline

Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 11, 2008
Enrollment StartApr 30, 2008
Primary CompletionDec 28, 2010
Study CompletionJan 6, 2011
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 18.2 years ago

Interventions

rimonabantdrug

double blind, placebo controlled, single 90 mg dose

placebodrug

matched placebo